New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Access Is Easy. Choosing the Right ETF Is Not

With 1,790 launches through July 2026, finding an ETF is easy and choosing one is not. 46% of share classes hold under $50 million, and nearly 7 in 10 allocators are reassessing their holdings, with portfolio fit the top criterion. See how 620 professionals select ETFs.

›ETF Issuers›Mirae Asset Global Investments›371470

371470

Mirae Asset TIGER Biotech Solactive ETF

Passive ETF Equity

Not rated

The 371470 Exchange Traded Fund (ETF) is provided by Mirae Asset Global Investments. It is built to track an index: Solactive China Biotech Index. The 371470 ETF provides physical exposure, so by buying it you actually own parts of all the 30 underlying holdings. This share class generates a stream of income by distributing dividends.

₩7,810

-₩55 (-0.70%) today

12:00 AM 10/15/26 Closed

1D price range

₩7,715₩7,970

52W price range

₩7,160₩9,680

YTD Perf.

-4.43%

YTD Flows

Annualized volatility

Fund AuM

€28M

Share class AuM

€28M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

KR7371470006

TER

0.59%

Inception date

12/3/2020

Issuer

Mirae Asset Global Investments

Benchmark

Solactive China Biotech Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
09820 Global X China Biotech ETF	-
KURE KraneShares MSCI All China Health Care Index ETF	-6.41%
83069 ChinaAMC Hang Seng Biotech ETF	-9.02%
03174 CSOP Hang Seng Biotech ETF	-9.06%
510310 E Fund Seeded CSI 300 ETF	-2.13%
510500 China Southern CSI 500 Index ETF	-3.65%
159949 China Huaan SZSE Chinext 50 ETF	-8.84%
82828 Hang Seng China Enterprises Index ETF	+1.45%
83188 ChinaAMC CSI 300 Index ETF	-2.14%
XCHA Xtrackers CSI300 Swap UCITS ETF	-2.88%
82823 iShares FTSE A50 China Index ETF	-3.05%
02801 iShares Core MSCI China ETF	-0.04%
CTEC iShares MSCI China Tech UCITS ETF	-3.08%
FLXC Franklin FTSE China UCITS ETF	-0.17%
82822 CSOP FTSE China A50 ETF	-1.97%

API

PerformanceDec 30, 2025 - Oct 14, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 08/31/26

Healthcare

99.69%

Unavailable

0.31%

Latest 371470 news

No content available for this fund

FAQ about 371470

371470 is a Passive ETF. This ETF provides exposure to Chinese Biotechnology Equities.

371470 tracks the Solactive China Biotech Index - CNY, through a optimized sampling replication method.

371470 carries a total expense ratio (TER) of 0.59%, indicating the annual cost for holding the fund.

371470 was introduced to the market on December 3, 2020. It trades on South Korea

Mirae Asset TIGER Biotech Solactive ETF, 371470, is provided by Mirae Asset Global Investments. Learn more about Mirae Asset Global Investments here.

371470 oversees €28M in assets as of October 14, 2026.

371470 follows a distributing dividend policy, meaning it pays out income to investors. As of October 14, 2026, its 12-month trailing yield was 0.74%.

As of August 31, 2026, 371470 has significant geographic allocations in China, Switzerland and Hong Kong.

As of August 31, 2026, 371470 focuses largely on Healthcare.

As of August 31, 2026, 371470 holds 30 positions in its portfolio, with 80.29% of assets concentrated in its top 15 holdings.

As of August 31, 2026, 371470 top three holdings include WuXi Biologics (Cayman), Inc., WuXi AppTec Co., Ltd. and BeOne Medicines Ltd..

The base currency of 371470 is KRW.

Top 10 holdings

Data as of 08/31/26

WuXi Biologics (Cayman), Inc.

10.82%

WuXi AppTec Co., Ltd.

10.41%

BeOne Medicines Ltd.

9.95%

Innovent Biologics, Inc.

9.72%

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

6.92%

Akeso, Inc.

5.68%

Sino Biopharmaceutical Ltd.

4.30%

Hansoh Pharmaceutical Group Co., Ltd.

3.97%

Genscript Biotech Corp.

3.33%

Pharmaron Beijing Co., Ltd.

3.13%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Access Is Easy. Choosing the Right ETF Is Not

Mirae Asset TIGER Biotech Solactive ETF

FAQ about 371470

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US